Halozyme Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Halozyme Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26% to $829,253,000. The net income raised on $281,594,000 and profit margin reached 34%. Total operating expenses were $299,318,000.
Profit Margin
| 2014 | 75.33M | -68.37M | -90.76% |
|---|---|---|---|
| 2015 | 135.05M | -32.23M | -23.86% |
| 2016 | 146.69M | -103.02M | -70.23% |
| 2017 | 316.61M | 62.97M | 19.89% |
| 2018 | 151.86M | -80.33M | -52.9% |
| 2019 | 195.99M | -72.24M | -36.86% |
| 2020 | 267.59M | 129.08M | 48.24% |
| 2021 | 443.31M | 402.71M | 90.84% |
| 2022 | 660.11M | 202.12M | 30.62% |
| 2023 | 829.25M | 281.59M | 33.96% |
0J2O.L Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 829.25M | 660.11M | 443.31M | 267.59M | 195.99M | 151.86M | 316.61M | 146.69M | 135.05M | 75.33M |
Cost of revenue | 192.36M | 139.30M | 81.41M | 43.36M | 45.54M | 10.13M | 31.15M | 33.20M | 29.24M | 22.73M |
Gross profit | 636.89M | 520.81M | 361.89M | 224.22M | 150.44M | 141.72M | 285.46M | 113.48M | 105.81M | 52.60M |
Operating exp. | ||||||||||
Research and development | 76.36M | 66.60M | 35.67M | 34.23M | 140.80M | 150.25M | 150.64M | 150.84M | 93.23M | 79.69M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 299.31M | 253.28M | 85.99M | 79.97M | 218.05M | 211.05M | 204.45M | 196.69M | 133.26M | 115.63M |
Operating income | 337.57M | 267.53M | 275.90M | 144.25M | -67.61M | -69.33M | 81.00M | -83.21M | -27.45M | -63.03M |
Other income (expenses), net | 10.75M | -18.61M | -27.38M | -14.95M | -4.64M | 7.57M | -19.39M | 1.32M | -4.77M | -5.33M |
Income before tax | 348.32M | 248.91M | 248.51M | 129.30M | -72.25M | -79.79M | 61.61M | -101.86M | -32.23M | -68.37M |
Income tax expense | 66.73M | 46.78M | -154.19M | 217K | -11K | 537K | -1.36M | 1.16M | 3.52M | 3.81M |
Net income | 281.59M | 202.12M | 402.71M | 129.08M | -72.24M | -80.33M | 62.97M | -103.02M | -32.23M | -68.37M |
Earnings per share | ||||||||||
Basic EPS | 2.13 | 1.48 | 2.86 | 0.95 | -0.5 | -0.56 | 0.46 | -0.81 | -0.25 | -0.56 |
Diluted EPS | 2.1 | 1.44 | 2.74 | 0.91 | -0.5 | -0.56 | 0.45 | -0.81 | -0.25 | -0.56 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |